Real-World Data you can trust, at scale.

EHR-derived insights from a federated hospital network. High-quality, validated, cNLP-enriched medical data, supported by a secure European infrastructure.

Selected collaborators and data partners

Our Pillars for High-Quality Real-World Evidence

Federated Analytics

Patient data does not need to leave the hospital. Deployment on-prem or in any cloud (kubernetes).

European Network

Access to a broad EU hospital footprint with on-prem extraction where available; built for multi-country studies.

Clinical NLP

OMOP-ready clinical NLP enriches structured EHR with outcomes, lines of therapy, Adverse Events, staging and more.

Quality Assurance

5 QA checks from intake to insight (completeness, accuracy, clinical validation, medical review, benchmark match).

Explore our longitudinal
EHR-extracted data-assets

 *estimated patient counts in our European data-assets (prior to inclusion/exclusion criteria) 

Data Quality at the Core

LynxCare’s Sentinel is a robust, OMOP Common Data Model-based system designed to continuously measure, benchmark, and improve EHR-derived datasets for regulatory compliance, collaborative studies, and translational research.

Join Europe’s Trusted
Health Data Network

Unlock real-world evidence with our federated cNLP platform.

EHDEN logo

FAQs

Find answers to your questions about our data solutions and services.

Can LynxCare support multi-center studies?

Yes, our OMOP CDM-based approach and federated network architecture enable multi-center, multi-country research collaborations while maintaining data privacy and regulatory compliance.

What makes LynxCare different from other healthcare data platforms?

We combine clinical NLP (not generic NLP), federated data architecture where hospitals retain full data control, OMOP CDM compliance for interoperability, rigorous 5-layer quality assurance from intake to insight and an EU hospital network for multi-site multi-country studies.

Where is LynxCare active?

Active in Belgium, the Netherlands, France, and Germany, with the ability to extend our European footprint for your research through established collaborations.